Literature DB >> 12358640

Comparative review of the pharmacokinetics of vitamin D analogues.

George R Bailie1, Curtis A Johnson.   

Abstract

This article reviews the pharmacokinetic characteristics of calcitriol, paricalcitol, and doxercalciferol, and provides an overview of the metabolism of vitamin D. Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis. Both are active on intravenous administration and little of the active agent remains in the circulation after 24 hours, although they are normally given every 48-72 hours. Doxercalciferol is a prohormone, requiring hepatic metabolism to the active metabolite 1alpha,25-(OH)2D2. The half-life of 1alpha,25-(OH)2D2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D. More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358640     DOI: 10.1046/j.1525-139x.2002.00086.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  10 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Hannah Santamaria; Nathaniel Solis; Cynthia Arbeeny; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-05

3.  Induction of CFTR gene expression by 1,25(OH)2 vitamin D3, 25OH vitamin D3, and vitamin D3 in cultured human airway epithelial cells and in mouse airways.

Authors:  Kristina M DiFranco; Jennifer K Mulligan; Aman S Sumal; Gill Diamond
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-24       Impact factor: 4.292

4.  Physiologically Based Pharmacokinetic Modeling of Vitamin D3 and Metabolites in Vitamin D-Insufficient Patients.

Authors:  Colton W Sawyer; Stacey M Tuey; Raymond E West; Thomas D Nolin; Melanie S Joy
Journal:  Drug Metab Dispos       Date:  2022-07-02       Impact factor: 3.579

Review 5.  New Vitamin D analogues for osteodystrophy in chronic kidney disease.

Authors:  John Cunningham
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

6.  Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Authors:  Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

Review 7.  Does the High Prevalence of Vitamin D Deficiency in African Americans Contribute to Health Disparities?

Authors:  Bruce N Ames; William B Grant; Walter C Willett
Journal:  Nutrients       Date:  2021-02-03       Impact factor: 5.717

8.  Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.

Authors:  Ditte Hansen; Lisbet Brandi; Knud Rasmussen
Journal:  BMC Nephrol       Date:  2009-09-24       Impact factor: 2.388

9.  The effects of calcitriol with calcium carbonate supplementation on inflammatory biomarkers in chronic kidney disease patients' with low vitamin D.

Authors:  Ruslinda Bt Mustafar; Rozita Mohd; Norazinizah Ahmad Miswan; Arba'ayah Bain; Rizna Cader; Abdul Halim Abdul Gafor; Marlyn Mohammad; Shamsul Azhar Shah; Nor Azmi Kamaruddin; Norella Ct Kong
Journal:  Cent Eur J Immunol       Date:  2014-06-27       Impact factor: 2.085

Review 10.  Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.

Authors:  Salvatore Di Maio; Ashraf T Soliman; Vincenzo De Sanctis; Christos C Kattamis
Journal:  Acta Biomed       Date:  2018-03-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.